Ab­b­Vie pres­i­dent Michael Sev­eri­no heads to Flag­ship as biotech in­cu­ba­tor's third CEO-part­ner in six days

4 years ago
People
Startups

AACR22: Af­ter Fer­Gene blowup, a start­up touts even bet­ter blad­der can­cer gene ther­a­py re­sults in tiny study

4 years ago
Startups
R&D

Af­ter Feb­ru­ary mar­ket crash, Pro­QR will lay off 30% of its work­force and try push­ing eye ther­a­py af­ter failed tri­al

4 years ago
People
R&D

Tiny Ok­la­homa com­pa­ny gets the eye of Boehringer In­gel­heim, sign­ing deal for re­gen­er­a­tive hear­ing loss treat­ment

4 years ago
Startups
Deals

'Tru­ly dif­fer­en­t': Roche's for­mer hema­tol­ogy leader shifts a new Ver­sant biotech in­to gear

4 years ago
Financing
Startups

In bid to re­make it­self af­ter pan­cre­at­ic can­cer flop, Halozyme ac­quires Antares and its drug de­liv­ery tech for $960M

4 years ago
Deals

As an­titrust case wraps, Mar­tin Shkre­li's lawyers say they're owed $2M+ in un­paid le­gal fees

4 years ago
People
Law

From $3M to $1.9B: Glax­o­SmithK­line in­serts dis­card­ed Gilead drug in­to late-stage port­fo­lio, buy­ing out the turn­around ...

4 years ago
Deals

RA, Jeito and Omega back a small Swiss biotech to en­ter an I/O field paved by Adap­ti­m­mune

4 years ago
Financing
Startups

FDA sends warn­ing to rogue phar­ma­cies sell­ing Adder­all il­le­gal­ly over the in­ter­net

4 years ago
FDA+

As­traZeneca’s on­col­o­gy R&D chief Su­san Gal­braith high­lights their next-gen prospects at #AACR22

4 years ago
R&D

Qui­et CD­MO makes noise, throw­ing down $500M for man­u­fac­tur­ing cam­pus and mov­ing for­ward with Chi­na op­er­a­tions

4 years ago
Pharma
Manufacturing

In­side the UK's push to ad­dress the an­timi­cro­bial cri­sis with a Net­flix-style sub­scrip­tion mod­el

4 years ago
Pharma

How a phar­ma com­pa­ny bought 2 ac­cel­er­at­ed ap­provals — nev­er ran con­fir­ma­to­ry tri­als — and cashed in un­til FDA ...

4 years ago
Pharma
FDA+

Drug pro­mo po­lice slap Bausch Health with un­ti­tled let­ter over pso­ri­a­sis drug TV and dig­i­tal mar­ket­ing

4 years ago
Pharma
FDA+

Abzena com­mits chunk of new $65M in­vest­ment to build out in hot North Car­oli­na scene

4 years ago
Pharma
Manufacturing

What hap­pened to all the 'good' drug names? In­side the mod­ern day dilem­ma of Rx nam­ing

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Coun­try mu­sic awards and more phar­ma ads; Bris­tol My­ers ad­vances clin­i­cal tri­al di­ver­si­ty ef­fort

4 years ago
Pharma
Marketing

Au­ri­on rais­es $120M in bid to scale cell ther­a­py for form of blind­ness

4 years ago
Startups

Five Prime tri­al in­ves­ti­ga­tor pleads guilty to $134K in­sid­er trad­ing scheme, faces up to 25 years in prison

4 years ago
Law

Stan­ford spin­out racks up more sup­port for its mR­NA ap­proach to cel­lu­lar re­ju­ve­na­tion

4 years ago
Financing
Startups

Backed by bil­lion­aire Mike Platt, En­gi­tix scores an­oth­er deal with Take­da to go af­ter IBD

4 years ago
Startups
Deals

Man­u­fac­tur­ing prob­lems trig­ger an­oth­er clin­i­cal hold for trou­bled Covid-19 vac­cine — lat­est in a string of ...

4 years ago
Coronavirus
Manufacturing

My­ovant and Pfiz­er’s path to se­cur­ing a sec­ond nod for Myfem­bree gets hazy — and in­vestors re­act quick­ly  

4 years ago
R&D
FDA+
First page Previous page 540541542543544545546 Next page Last page
A service from the Financial Times